Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.I. F. Tannock, K C Murphy, David Osoba et al.|Journal of Clinical Oncology|1996Cited by 1.6k
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|The Lancet Oncology|2015Cited by 244
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Axel Hauschild, Karen Bartley et al.|European Journal of Dermatology|2018Cited by 26
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.Reinhard Dummer, Axel Hauschild, Nicole Basset‐Séguin et al.|Journal of Clinical Oncology|2015Cited by 22
3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE studyJohan Hansson, Axel Hauschild, Karen Bartley et al.|European Journal of Cancer|2015Cited by 2